Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HTG MOLECULAR DIAGNOSTICS, INC.

(HTGM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
3.88(c) 3.94(c) 3.68(c) 3.55(c) 3.5 Last
25 462 35 998 31 578 34 864 29 965 Volume
-0.51% +1.55% -6.60% -3.53% -1.41% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 8,84 M - -
Net income 2021 -16,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,49x
Yield 2021 -
Sales 2022 15,3 M - -
Net income 2022 -19,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,86x
Yield 2022 -
Capitalization 34,7 M 34,7 M -
Capi. / Sales 2021 3,93x
Capi. / Sales 2022 2,27x
Nbr of Employees 84
Free-Float 87,5%
More Financials
Company
HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company's HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The... 
More about the company
Ratings of HTG Molecular Diagnostics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about HTG MOLECULAR DIAGNOSTICS, INC.
11/17HTG Molecular Diagnostics, Icahn Mount Sinai Enter Bladder Cancer Research Collaboratio..
MT
11/17HTG and Icahn School of Medicine at Mount Sinai Announce Bladder Cancer Research Collab..
GL
11/17HTG Molecular Diagnostics, Inc. and Icahn School of Medicine at Mount Sinai Announce Bl..
CI
11/10HTG Molecular Diagnostics Reports Third Quarter 2021 Results - Form 8-K
PU
11/10HTG MOLECULAR DIAGNOSTICS, INC Management's Discussion and Analysis of Financial Condi..
AQ
11/10HTG Molecular Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine..
CI
11/10HTG Molecular Diagnostics Reports Third Quarter 2021 Results
AQ
11/02HTG Molecular Diagnostics to Announce Third Quarter 2021 Financial Results and Host Co..
GL
10/05HTG MOLECULAR DIAGNOSTICS : Expands Therapeutics Team
AQ
10/05HTG Molecular Diagnostics, Inc. Appoints Stephen Barat as Senior Vice President of Ther..
CI
09/29HTG MOLECULAR DIAGNOSTICS : Material Definitive Agreement (Form 8-K)
PU
09/29HTG MOLECULAR DIAGNOSTICS, INC : Entry into a Material Definitive Agreement, Financial Sta..
AQ
09/29HTG Molecular Diagnostics, Inc. Enters into Third and Fourth Amendment to Its Standard ..
CI
09/21HTG MOLECULAR DIAGNOSTICS : to Present at the Cantor Fitzgerald Virtual Global Healthcare ..
AQ
09/08HTG MOLECULAR DIAGNOSTICS : to Present at H.C. Wainwright's 23rd Annual Global Investment ..
AQ
More news
News in other languages on HTG MOLECULAR DIAGNOSTICS, INC.
11/17HTG Molecular Diagnostics et Icahn Mount Sinai concluent une collaboration pour la rech..
08/12Earnings Flash (HTGM) HTG MOLECULAR DIAGNOSTICS affiche un chiffre d'affaires de 2,1 mi..
06/22HTG Molecular Diagnostics reçoit les premières commandes commerciales pour le panel tra..
More news
Analyst Recommendations on HTG MOLECULAR DIAGNOSTICS, INC.
More recommendations
Chart HTG MOLECULAR DIAGNOSTICS, INC.
Duration : Period :
HTG Molecular Diagnostics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HTG MOLECULAR DIAGNOSTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 3,50 $
Average target price 9,67 $
Spread / Average Target 176%
EPS Revisions
Managers and Directors
John L. Lubniewski President, Chief Executive Officer & Director
Shaun D. McMeans CFO, Secretary, Treasurer & SVP-Administration
Ann F. Hanham Chairman
Harry Allan George Independent Director
Lee Roy McCracken Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HTG MOLECULAR DIAGNOSTICS, INC.-23.17%35
SARTORIUS AG43.48%41 235
BIOTAGE AB (PUBL)88.49%1 912
REVENIO GROUP OYJ9.64%1 657
VAREX IMAGING CORPORATION69.48%1 129
CELLAVISION AB (PUBL)7.17%868